---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-232754"
form_type: "8-K"
ticker: null
cik: "0001604950"
company_name: "scPharmaceuticals Inc."
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:26:30.016120+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# MannKind completes acquisition of scPharmaceuticals for $5.35/sh plus CVR; stock delisted

## Summary
- Merger closed Oct 7, 2025; shareholders receive $5.35 cash + up to $1.00 CVR per share.
- Approximately 84.4% of shares tendered (73.5% valid tender + 10.9% guaranteed delivery).
- Company terminated existing credit agreement and repurchased revenue participation rights upon merger close.
- All directors resigned; new board appointed from MannKind (Michael Castagna, David Thomson, Chris Prentiss).
- Shares halted on Nasdaq; company will file Form 15 to deregister reporting obligations.

## SEC filing metadata
- accession: 0001193125-25-232754
- form_type: 8-K
- cik: 0001604950
- company_name: scPharmaceuticals Inc.
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604950/000119312525232754/0001193125-25-232754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604950/000119312525232754/d20686d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-232754
- JSON: https://secwatch.observer/filing/0001193125-25-232754.json
- Plain text: https://secwatch.observer/filing/0001193125-25-232754.txt

## Source-grounded claims
- claim_id: 2061095a0caa4e5b77f4e3c449d04b4fc1035ae9
  claim: scPharmaceuticals Inc.: Second amended and restated certificate of incorporation amended and restated in entirety (effective 2025-10-07).
  evidence_excerpt: on October 7, 2025, the Company’s second amended and restated certificate of incorporation and amended and restated bylaws were each amended and restated in their entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604950/000119312525232754/0001193125-25-232754-index.htm
- claim_id: 6290035b805eaaa86cc189f52cf7804fb1ffd60c
  claim: scPharmaceuticals Inc.: Amended and restated bylaws amended and restated in entirety (effective 2025-10-07).
  evidence_excerpt: on October 7, 2025, the Company’s second amended and restated certificate of incorporation and amended and restated bylaws were each amended and restated in their entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604950/000119312525232754/0001193125-25-232754-index.htm
- claim_id: 6f7f42f02e69f8588d53d51ae64e02c58809d781
  claim: scPharmaceuticals Inc. underwent a change of control involving MannKind Corporation for $5.35 in cash plus one non-tradable contingent value right per Share (closed 2025-10-07).
  evidence_excerpt: commenced a tender offer to purchase all the outstanding shares of the Company’s common stock, par value $0.0001 per share (the “ Shares ”), at a price per Share of (i) $5.35 in cash (the “ Cash Amount ”), without interest, subject to any applicable withholding taxes and (ii) one non-tradable contingent value right (each, a “ CVR ”) per Share, which
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604950/000119312525232754/0001193125-25-232754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.